MedTrace Logo

Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents

NCT03056118 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1368

Last updated 2017-02-17

No results posted yet for this study

Summary

Investigators try to assess the safety of 6-months or 12-months maintenance of dual antiplatelet therapy (DAPT, aspirin + clopidogrel) in patients undergoing percutaneous coronary intervention using the Zotarolimus-eluting, Resolute Integrity™ stent (Medtronic Vascular Inc, Santa Rosa, CA) or the BioMatrix™ stent (Biosensors. Singapore).

Conditions

  • Ischemic Heart Disease

Interventions

DRUG

6-month dual anti-platelet therapy

Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 6 months

DRUG

12-month dual anti-platelet therapy

Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 12 months

DEVICE

Zotarolimus eluting stent

Zotarolimus eluting stent is applied to coronary stenotic lesion

DEVICE

Biolimus eluting stent

Biolimus eluting stent is applied to coronary stenotic lesion

Sponsors & Collaborators

  • Gangnam Severance Hospital

    lead OTHER

Principal Investigators

  • Hyuck moon Kwon · Gangnam Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-02
Primary Completion
2015-06-01
Completion
2015-09-07

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03056118 on ClinicalTrials.gov